Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan: An Interrupted Time Series Analysis.
- 1Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital Sendai Japan.
- 2Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University Sendai Japan.
Abstract
Background
Sodium-glucose co-transporter 2 (SGLT2) inhibitors and loop diuretics have beneficial diuretic effects in patients with heart failure but may increase the risk of excessive water loss. Therefore, clinical guidelines recommend adjustment of loop diuretic doses when these agents are used concomitantly. However, real-world evidence regarding changes in loop diuretic dosing is limited. This study evaluated changes in prescribed doses of oral loop diuretics in patients with heart failure receiving dapagliflozin or empagliflozin before and after publication of the JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure.Methods and results
Changes in prescribed dose trends were evaluated using monthly aggregated prescription data obtained from the Medical Data Vision database (Medical Data Vision, Inc., Tokyo, Japan). After publication of the guideline, statistically significant decreases were observed in the empagliflozin-prescribed group for azosemide (-0.1756 mg/month; P=0.0360), furosemide (-0.2180 mg/month; P=0.0485), and torsemide (-0.0387 mg/month; P=0.0378), and in the dapagliflozin-prescribed group for azosemide (-0.8221 mg/month; P=0.0260). The study period for dapagliflozin was too short to provide adequate statistical power.Conclusions
The publication of the JCS/JHFS 2021 guideline was associated with decreases in prescribed doses of oral loop diuretics. Dose reduction of oral loop diuretics may be considered in patients receiving concomitant SGLT2 inhibitors in clinical practice.
Related
- Intensification of blood pressure lowering therapeutics based on diuretics versus usual management for uncontrolled hypertension in patients with moderate to severe chronic kidney disease (THINK): protocol for an open label, two-parallel group, cluster randomised controlled, superiority, phase 3 trial
- Dapagliflozin vs. Acetazolamide in Patients With Acute Heart Failure: A Randomized Controlled Trial (CHOICE‐AHF)
- Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease
- Real-World Renal Effects of Dapagliflozin in Bulgarian Patients with Chronic Kidney Disease of Predominantly Glomerular Origin: A Two-Year Comparative Cohort Study with Historical Controls
- Antialbuminuric Effect of Dapagliflozin Correlates With Urinary Epidermal Growth Factor in Real-World Patients With Diabetic Kidney Disease
BibTeX
@article{miura2026trends,
title = {{Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan: An Interrupted Time Series Analysis.}},
author = {Ryosuke Miura and Kouji Okada},
journal = {Circulation reports},
year = {2026},
month = sep,
doi = {10.1253/circrep.cr-26-0142},
url = {https://europepmc.org/article/MED/43011108},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan: An Interrupted Time Series Analysis.
AU - Ryosuke Miura
AU - Kouji Okada
PY - 2026
DA - 2026/09/11
JO - Circulation reports
DO - 10.1253/circrep.cr-26-0142
UR - https://europepmc.org/article/MED/43011108
AB - Background Sodium-glucose co-transporter 2 (SGLT2) inhibitors and loop diuretics have beneficial diuretic effects in patients with heart failure but may increase the risk of excessive water loss. Therefore, clinical guidelines recommend adjustment of loop diuretic doses when these agents are used concomitantly. However, real-world evidence regarding changes in loop diuretic dosing is limited. This study evaluated changes in prescribed doses of oral loop diuretics in patients with heart failure receiving dapagliflozin or empagliflozin before and after publication of the JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure.Methods and results Changes in prescribed dose trends were evaluated using monthly aggregated prescription data obtained from the Medical Data Vision database (Medical Data Vision, Inc., Tokyo, Japan). After publication of the guideline, statistically significant decreases were observed in the empagliflozin-prescribed group for azosemide (-0.1756 mg/month; P=0.0360), furosemide (-0.2180 mg/month; P=0.0485), and torsemide (-0.0387 mg/month; P=0.0378), and in the dapagliflozin-prescribed group for azosemide (-0.8221 mg/month; P=0.0260). The study period for dapagliflozin was too short to provide adequate statistical power.Conclusions The publication of the JCS/JHFS 2021 guideline was associated with decreases in prescribed doses of oral loop diuretics. Dose reduction of oral loop diuretics may be considered in patients receiving concomitant SGLT2 inhibitors in clinical practice.
SN - 2434-0790
ER -